• Wenyan Zhou, Tian Liu, Xian Xiao, and Jing He.
• Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China.
• Medicine (Baltimore). 2022 Oct 21; 101 (42): e31173e31173.

RationaleBehçet's disease (BD) is an autoimmune disease presented with recurrent oral aphthous ulcers, genital ulcers, uveitis and skin lesions. The cutaneous manifestations are often refractory and more resistant to conventional therapy. This report provides a new treatment of low-dose interleukin-2 (IL-2) with refractory BD patient.Patient ConcernsA 37-year-old female patient experienced oral ulcer and erythema nodosum on the right leg for over 12 months and resisted to Methylprednisolone and Thalidomide.DiagnosesThe patient suffered from recurrent painful oral ulceration and an erythema nodosum. Pathergy test is also positive. Thus, we diagnosed her as BD according to the International Criteria for Behçet's Disease (ICBD).InterventionsThe patient took Methylprednisolone 8 mg qd, Thalidomide 50 mg qn and Hydroxychloroquine 200 mg bid successively as treatment. However, the medicine didn't take effect. Finally, this patient was given low-dose IL-2 intramuscular injection qod for 3 months.OutcomesOral ulcers and the erythema disappeared and the patient has been symptom-free for 6 months.Lessonslow-dose IL-2 is a safe and effective treatment for refractory BD.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

19 keywords...

hide…